MANNKIND CORP (MNKD) Stock Fundamental Analysis
NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD
Overall MNKD gets a fundamental rating of 5 out of 10. We evaluated MNKD against 560 industry peers in the Biotechnology industry. Both the profitability and the financial health of MNKD get a neutral evaluation. Nothing too spectacular is happening here. MNKD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination!
1. Profitability
1.1 Basic Checks
MNKD had positive earnings in the past year.
In the past year MNKD had a positive cash flow from operations.
In the past 5 years MNKD reported 4 times negative net income.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
1.2 Ratios
MNKD has a Return On Assets of 7.23%. This is amongst the best in the industry. MNKD outperforms 93.57% of its industry peers.
With an excellent Return On Invested Capital value of 22.19%, MNKD belongs to the best of the industry, outperforming 97.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROIC | 22.19% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MNKD's Profit Margin of 9.96% is amongst the best of the industry. MNKD outperforms 93.39% of its industry peers.
MNKD's Operating Margin of 27.25% is amongst the best of the industry. MNKD outperforms 97.14% of its industry peers.
MNKD has a better Gross Margin (75.77%) than 83.21% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
MNKD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for MNKD has been increased compared to 1 year ago.
Compared to 5 years ago, MNKD has more shares outstanding
MNKD has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -7.44, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
MNKD has a Altman-Z score of -7.44. This is in the lower half of the industry: MNKD underperforms 68.39% of its industry peers.
MNKD has a debt to FCF ratio of 13.30. This is a negative value and a sign of low solvency as MNKD would need 13.30 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 13.30, MNKD belongs to the best of the industry, outperforming 92.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Altman-Z | -7.44 |
ROIC/WACC2.39
WACC9.27%
2.3 Liquidity
A Current Ratio of 2.36 indicates that MNKD has no problem at all paying its short term obligations.
MNKD's Current ratio of 2.36 is on the low side compared to the rest of the industry. MNKD is outperformed by 71.25% of its industry peers.
MNKD has a Quick Ratio of 2.11. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD has a Quick ratio of 2.11. This is in the lower half of the industry: MNKD underperforms 72.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 |
3. Growth
3.1 Past
MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 166.67%, which is quite impressive.
MNKD shows a strong growth in Revenue. In the last year, the Revenue has grown by 32.48%.
The Revenue has been growing by 35.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
3.2 Future
The Earnings Per Share is expected to grow by 43.66% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.37% on average over the next years. This is quite good.
EPS Next Y129.5%
EPS Next 2Y77%
EPS Next 3Y57.82%
EPS Next 5Y43.66%
Revenue Next Year13.77%
Revenue Next 2Y13.56%
Revenue Next 3Y12.78%
Revenue Next 5Y14.37%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 51.50, MNKD can be considered very expensive at the moment.
92.14% of the companies in the same industry are more expensive than MNKD, based on the Price/Earnings ratio.
MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.19.
With a Price/Forward Earnings ratio of 16.44, MNKD is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 93.57% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.13, MNKD is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.5 | ||
| Fwd PE | 16.44 |
4.2 Price Multiples
MNKD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MNKD is cheaper than 95.36% of the companies in the same industry.
93.21% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.4 | ||
| EV/EBITDA | 13.35 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 57.82% in the coming years.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y77%
EPS Next 3Y57.82%
5. Dividend
5.1 Amount
MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.12
+0.05 (+1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners61.62%
Inst Owner Change6.07%
Ins Owners1.42%
Ins Owner Change6.81%
Market Cap1.25B
Analysts86.15
Price Target10.49 (154.61%)
Short Float %8.73%
Short Ratio12.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.59%
Min EPS beat(2)-18.3%
Max EPS beat(2)-10.87%
EPS beat(4)0
Avg EPS beat(4)-77.7%
Min EPS beat(4)-246.98%
Max EPS beat(4)-10.87%
EPS beat(8)3
Avg EPS beat(8)-19.02%
EPS beat(12)5
Avg EPS beat(12)-10.38%
EPS beat(16)6
Avg EPS beat(16)-8.65%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.38%
Max Revenue beat(2)0.9%
Revenue beat(4)3
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)3.43%
Revenue beat(12)9
Avg Revenue beat(12)6.54%
Revenue beat(16)12
Avg Revenue beat(16)6.34%
PT rev (1m)2.86%
PT rev (3m)2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5%
EPS NY rev (1m)-1.56%
EPS NY rev (3m)-26.53%
Revenue NQ rev (1m)-0.39%
Revenue NQ rev (3m)-1.64%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)-4.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.5 | ||
| Fwd PE | 16.44 | ||
| P/S | 4.21 | ||
| P/FCF | 57.4 | ||
| P/OCF | 42.55 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.35 |
EPS(TTM)0.08
EY1.94%
EPS(NY)0.25
Fwd EY6.08%
FCF(TTM)0.07
FCFY1.74%
OCF(TTM)0.1
OCFY2.35%
SpS0.98
BVpS-0.19
TBVpS-0.22
PEG (NY)0.4
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.23% | ||
| ROE | N/A | ||
| ROCE | 27.56% | ||
| ROIC | 22.19% | ||
| ROICexc | 49.27% | ||
| ROICexgc | 51.75% | ||
| OM | 27.25% | ||
| PM (TTM) | 9.96% | ||
| GM | 75.77% | ||
| FCFM | 7.33% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 13.3 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 93.83% | ||
| Cap/Sales | 2.56% | ||
| Interest Coverage | 5.56 | ||
| Cash Conversion | 33% | ||
| Profit Quality | 73.61% | ||
| Current Ratio | 2.36 | ||
| Quick Ratio | 2.11 | ||
| Altman-Z | -7.44 |
F-Score7
WACC9.27%
ROIC/WACC2.39
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y129.5%
EPS Next 2Y77%
EPS Next 3Y57.82%
EPS Next 5Y43.66%
Revenue 1Y (TTM)32.48%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%18.25%
Revenue Next Year13.77%
Revenue Next 2Y13.56%
Revenue Next 3Y12.78%
Revenue Next 5Y14.37%
EBIT growth 1Y161.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y130.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y148.04%
OCF growth 3YN/A
OCF growth 5YN/A